JPS58135818A - 貯蔵寿命の長い高酸素輸送能力を有する交叉結合されたヘモグロビン剤の製法 - Google Patents
貯蔵寿命の長い高酸素輸送能力を有する交叉結合されたヘモグロビン剤の製法Info
- Publication number
- JPS58135818A JPS58135818A JP57193572A JP19357282A JPS58135818A JP S58135818 A JPS58135818 A JP S58135818A JP 57193572 A JP57193572 A JP 57193572A JP 19357282 A JP19357282 A JP 19357282A JP S58135818 A JPS58135818 A JP S58135818A
- Authority
- JP
- Japan
- Prior art keywords
- oxygen
- cross
- hemoglobin
- agent
- linked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000001301 oxygen Substances 0.000 title claims abstract description 38
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 38
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 102000001554 Hemoglobins Human genes 0.000 title claims abstract description 27
- 108010054147 Hemoglobins Proteins 0.000 title claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 239000003814 drug Substances 0.000 title description 6
- 238000003860 storage Methods 0.000 title description 5
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 14
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 21
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 229920006037 cross link polymer Polymers 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 claims 1
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 229940070891 pyridium Drugs 0.000 claims 1
- 238000004132 cross linking Methods 0.000 abstract description 11
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 4
- 239000012636 effector Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 27
- 238000009826 distribution Methods 0.000 description 12
- 230000009467 reduction Effects 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003431 cross linking reagent Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000012510 hollow fiber Substances 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 229960001327 pyridoxal phosphate Drugs 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 241001233037 catfish Species 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- QTWZICCBKBYHDM-UHFFFAOYSA-N leucomethylene blue Chemical compound C1=C(N(C)C)C=C2SC3=CC(N(C)C)=CC=C3NC2=C1 QTWZICCBKBYHDM-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000002926 oxygen Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 101710169603 Hemoglobin-1 Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000981375 Homo sapiens Nuclear cap-binding protein subunit 1 Proteins 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100024372 Nuclear cap-binding protein subunit 1 Human genes 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- -1 inosyl phosphate Chemical compound 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- JUXPPFZURUWURG-UHFFFAOYSA-N phosphoric acid 1H-pyridin-2-one Chemical compound P(=O)(O)(O)O.OC1=NC=CC=C1 JUXPPFZURUWURG-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000003454 tympanic membrane Anatomy 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3144705A DE3144705C2 (de) | 1981-11-11 | 1981-11-11 | Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat |
| DE3144705.8 | 1981-11-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58135818A true JPS58135818A (ja) | 1983-08-12 |
| JPH0365326B2 JPH0365326B2 (enExample) | 1991-10-11 |
Family
ID=6146080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57193572A Granted JPS58135818A (ja) | 1981-11-11 | 1982-11-05 | 貯蔵寿命の長い高酸素輸送能力を有する交叉結合されたヘモグロビン剤の製法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4777244A (enExample) |
| EP (1) | EP0078961B1 (enExample) |
| JP (1) | JPS58135818A (enExample) |
| AT (1) | ATE22803T1 (enExample) |
| DE (2) | DE3144705C2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01501471A (ja) * | 1986-06-20 | 1989-05-25 | ノースフイールド ラボラトリーズ インコーポレイテツド | 非細胞性赤血球代替品 |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4529719A (en) * | 1983-05-04 | 1985-07-16 | Tye Ross W | Modified crosslinked stroma-free tetrameric hemoglobin |
| DE3320752A1 (de) * | 1983-06-09 | 1984-12-13 | Wolfgang Prof. Dr.Dr. 6500 Mainz Barnikol | Lumineszierende schichten zur verwendung in vorrichtungen zur bestimmung der sauerstoffkonzentration in gasen und dergleichen durch messung der lumineszensverringerung |
| GB8328917D0 (en) * | 1983-10-28 | 1983-11-30 | Fisons Plc | Blood substitute |
| DE3340592A1 (de) * | 1983-11-10 | 1985-05-23 | B. Braun Melsungen Ag, 3508 Melsungen | Konjugate makromolekularer verbindungen an haemoglobine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel |
| US5281579A (en) * | 1984-03-23 | 1994-01-25 | Baxter International Inc. | Purified virus-free hemoglobin solutions and method for making same |
| USRE34271E (en) * | 1984-06-27 | 1993-06-01 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
| NL8403425A (nl) * | 1984-11-09 | 1986-06-02 | Stichting Gastransport | Stromavrije hemoglobine-oplossing, werkwijze voor de bereiding daarvan en toepassing daarvan. |
| DE3501349A1 (de) * | 1985-01-17 | 1986-07-17 | Battelle-Institut E.V., 6000 Frankfurt | Blutersatz |
| DE3525272A1 (de) * | 1985-07-16 | 1987-01-29 | Biotest Pharma Gmbh | Verfahren zur herstellung vernetzter haemoglobin-praeparate mit enger molekulargewichtsverteilung |
| FR2600894B1 (fr) * | 1986-07-02 | 1989-01-13 | Centre Nat Rech Scient | Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications |
| GB8711614D0 (en) * | 1987-05-16 | 1987-06-24 | Medical Res Council | Proteins |
| US5449759A (en) * | 1987-05-16 | 1995-09-12 | Somatogen, Inc. | Hemoglobins with intersubunit desulfide bonds |
| GB8712240D0 (en) * | 1987-05-23 | 1987-07-01 | Fisons Plc | Pharmaceutical formulation |
| US5545727A (en) * | 1989-05-10 | 1996-08-13 | Somatogen, Inc. | DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin |
| US6150506A (en) * | 1989-05-10 | 2000-11-21 | Baxter Biotech Technology Sarl | Modified hemoglobin-like compounds and methods of purifying same |
| US5844090A (en) * | 1994-05-09 | 1998-12-01 | Somatogen, Inc. | Modified hemoglobin-like compounds |
| US5599907A (en) * | 1989-05-10 | 1997-02-04 | Somatogen, Inc. | Production and use of multimeric hemoglobins |
| US5234903A (en) * | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
| US5439882A (en) * | 1989-12-29 | 1995-08-08 | Texas Tech University Health Sciences Center | Blood substitute |
| AU658821B2 (en) * | 1990-03-14 | 1995-05-04 | University Of Toronto Innovations Foundation, The | Acyl phosphate esters and modification of proteins therewith |
| US5352773A (en) * | 1990-08-06 | 1994-10-04 | Baxter International Inc. | Stable hemoglobin based composition and method to store same |
| AU9067791A (en) * | 1990-11-20 | 1992-06-11 | Enzon, Inc. | Method of enhancing long-term storage stability of hemoglobin products |
| HUT64571A (en) * | 1990-11-29 | 1994-01-28 | Upjohn Co | A method for producing hemoglobin preparatives containing imido ester cross bind |
| US5250665A (en) * | 1991-05-31 | 1993-10-05 | The University Of Toronto Innovations Foundation | Specifically β-β cross-linked hemoglobins and method of preparation |
| EP0611306B1 (en) * | 1991-11-08 | 1998-07-08 | Somatogen, Inc. | Hemoglobins as drug delivery agents |
| US5344393A (en) * | 1992-02-28 | 1994-09-06 | Alliance Pharmaceutical Corp. | Use of synthetic oxygen carriers to facilitate oxygen delivery |
| US5264555A (en) * | 1992-07-14 | 1993-11-23 | Enzon, Inc. | Process for hemoglobin extraction and purification |
| DK145092D0 (enExample) * | 1992-12-03 | 1992-12-03 | Novo Nordisk As | |
| SE9301581D0 (sv) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Protein formulation |
| US6242417B1 (en) | 1994-03-08 | 2001-06-05 | Somatogen, Inc. | Stabilized compositions containing hemoglobin |
| US5631219A (en) * | 1994-03-08 | 1997-05-20 | Somatogen, Inc. | Method of stimulating hematopoiesis with hemoglobin |
| DE4418973A1 (de) * | 1994-05-31 | 1995-12-14 | Barnikol Wolfgang | Verfahren zur Herstellung molekular-einheitlicher hyperpolymerer Hämoglobine |
| US5929031A (en) * | 1995-05-02 | 1999-07-27 | Baxter Biotech Technology Sarl | Storage stable hemoglobin solutions |
| US6359114B1 (en) * | 1995-06-07 | 2002-03-19 | Aphton Corp. | System for method for the modification and purification of proteins |
| US5865784A (en) * | 1995-06-07 | 1999-02-02 | Alliance Pharmaceutical Corp. | Method of hemodilution facilitated by monitoring oxygenation status |
| US5814601A (en) * | 1997-02-28 | 1998-09-29 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
| ATE302019T1 (de) * | 1997-02-28 | 2005-09-15 | Univ California | Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen |
| AU784195B2 (en) | 1999-11-12 | 2006-02-16 | Baxter Biotech Technology S.A.R.L. | Reduced side-effect hemoglobin compositions |
| US20030153491A1 (en) * | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| US20050164915A1 (en) * | 2002-04-01 | 2005-07-28 | Sangart, Inc. | Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| JP3912206B2 (ja) * | 2002-07-05 | 2007-05-09 | 株式会社日立製作所 | 筒内直接燃料噴射装置用燃料ポンプ |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51109983A (enExample) * | 1975-02-27 | 1976-09-29 | Alza Corp | |
| JPS52154515A (en) * | 1976-04-23 | 1977-12-22 | Biotest Serum Institut Gmbh | Hemoglobin preparation strengthening oxygen release property |
| JPS5449314A (en) * | 1977-09-06 | 1979-04-18 | Studiengesellschaft Kohle Mbh | Improving of oxygen discharging property of erythrocyte |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2449885C3 (de) * | 1974-10-21 | 1980-04-30 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat |
| US4061736A (en) * | 1975-02-02 | 1977-12-06 | Alza Corporation | Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin |
| US4136093A (en) * | 1976-04-23 | 1979-01-23 | Biotest-Serum-Institut Gmbh | Hemoglobin preparation with increased oxygen release |
| DE2714252C2 (de) * | 1977-03-31 | 1983-08-18 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung eines für die intravenöse Injektion geeigneten Hämoglobinpräparates mit erhöhter Sauerstoffabgabe gegenüber Erythrozyten |
| DE2617822C3 (de) * | 1976-04-23 | 1981-01-08 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung eines für die intravenöse Injektion geeigneten Hämoglobinpräparates mit erhöhter Sauerstoffabgabe gegenüber Erythrozyten |
-
1981
- 1981-11-11 DE DE3144705A patent/DE3144705C2/de not_active Expired
-
1982
- 1982-10-23 DE DE8282109808T patent/DE3273731D1/de not_active Expired
- 1982-10-23 EP EP82109808A patent/EP0078961B1/de not_active Expired
- 1982-10-23 AT AT82109808T patent/ATE22803T1/de not_active IP Right Cessation
- 1982-11-05 JP JP57193572A patent/JPS58135818A/ja active Granted
-
1987
- 1987-05-08 US US07/047,819 patent/US4777244A/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51109983A (enExample) * | 1975-02-27 | 1976-09-29 | Alza Corp | |
| JPS52154515A (en) * | 1976-04-23 | 1977-12-22 | Biotest Serum Institut Gmbh | Hemoglobin preparation strengthening oxygen release property |
| JPS5449314A (en) * | 1977-09-06 | 1979-04-18 | Studiengesellschaft Kohle Mbh | Improving of oxygen discharging property of erythrocyte |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01501471A (ja) * | 1986-06-20 | 1989-05-25 | ノースフイールド ラボラトリーズ インコーポレイテツド | 非細胞性赤血球代替品 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3144705A1 (de) | 1983-05-19 |
| EP0078961A2 (de) | 1983-05-18 |
| ATE22803T1 (de) | 1986-11-15 |
| JPH0365326B2 (enExample) | 1991-10-11 |
| EP0078961B1 (de) | 1986-10-15 |
| EP0078961A3 (en) | 1983-07-27 |
| DE3144705C2 (de) | 1983-12-08 |
| DE3273731D1 (en) | 1986-11-20 |
| US4777244A (en) | 1988-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS58135818A (ja) | 貯蔵寿命の長い高酸素輸送能力を有する交叉結合されたヘモグロビン剤の製法 | |
| DE3790322C2 (de) | Nichtzellulares Präparat als Ersatz für rote Blutkörperchen | |
| EP0912197B1 (de) | Hämoglobin-hydroxyethylstärke-konjugate als sauerstoff-transport-mittel | |
| US4136093A (en) | Hemoglobin preparation with increased oxygen release | |
| DE2417619C2 (de) | Intramolekular vernetztes Hämoglobin, Verfahren zu dessen Herstellung und seine Verwendung | |
| US20020062007A1 (en) | Acellular red blood cell substitute | |
| DE2607706A1 (de) | Wasserloesliches, polymerisiertes haemoglobin | |
| Iwasaki et al. | Preparation and evaluation of hemoglobin‐polyethylene glycol conjugate (pyridoxalated polyethylene glycol hemoglobin) as an oxygen‐carrying resuscitation fluid | |
| US20080108555A1 (en) | Method and Apparatus for Preparing an Acellular Red Blood Cell Substitute | |
| EA020891B1 (ru) | Способ изготовления высокоочищенной фармацевтической композиции | |
| EA017871B1 (ru) | Кровезаменитель с функцией переноса кислорода, фармацевтическая композиция (варианты) | |
| RU2337705C2 (ru) | Растворы полимеризованного гемоглобина с пониженным количеством тетрамера и способ их получения | |
| ES2395894T3 (es) | Hemoglobinas de mamífero compatibles con plasma sanguíneo, reticuladas y conjugadas con poli(óxidos de alquileno) como portadores de oxígeno médicos artificiales, su preparación y su uso | |
| DE69625605T2 (de) | Die herstellung von hämoglobinen pharmazeutischer qualität durch eine hitzebehandlung in teilweise oxygenierter form | |
| DE69815769T2 (de) | Antitumormittel enthaltend einen Komplex einer Oxidoreduktase und eines Polymers und ein Substrat des Enzyms | |
| CN1196713C (zh) | 用于红细胞代用品的交联血红蛋白的制备方法 | |
| RU2167932C1 (ru) | Способ производства водки | |
| DE2428982A1 (de) | Verfahren zur herstellung einer blutfraktion | |
| DE69130483T2 (de) | Verbesserter blutersatz | |
| CH638401A5 (en) | Process for the preparation of haemoglobin preparations having an increased oxygen delivery | |
| JPS61103824A (ja) | ポリリボイノシン酸・ポリリボシチヂル酸・ポリ−レ−リジン複合体の注射用製剤の新規調製法 | |
| RU2245150C1 (ru) | Полифункциональный кровезаменитель | |
| RU1748324C (ru) | Способ получения препарата стрептодеказы | |
| KR100562762B1 (ko) | 무세포성적혈구대체물을제조하기위한방법및장치 | |
| Geyer | biotics and are sterilized by filtration through a 0.2 micron Millipore filter |